Lably
Skip to content

Related on Lably

Through Electrode, Potassium and Experience

The implant has two main components. The outside component is the sound processor, which contains microphones, electronics that include digital signal processor (DSP) chips, battery, and a coil that transmits a signal to the implant across the skin. It is generally worn behind the ear, though some self-contained sound processors take the form of a pebble-shaped unit worn directly on the side of the head over the implant site, held in place by magnetic attraction to the internal implant. The sound processor could also be attached to clothing, for example, in the case of young children. The inside component is the actual implant, which contains a coil to receive signals, electronics, and an array of electrodes that stimulate the cochlear nerve, which is placed into the cochlea.

The surgical procedure is performed under general anesthesia. Surgical risks are minimal, and most individuals will undergo outpatient surgery and go home the same day. However, some individuals will experience dizziness, and on rare occasions, tinnitus or facial nerve bruising.

From the early days of implants in the 1970s and 1980s, speech perception via an implant improved greatly, though gains have plateaued since the introduction of modern sound coding strategies in the 1990s. More than 200,000 people in the United States had received a CI through 2019. Many users of modern implants gain reasonable to good hearing and speech perception skills post-implantation, especially when combined with lipreading. One of the challenges that remain with these implants is that hearing and speech understanding skills after implantation show a wide range of variation across individual implant users. Factors such as age of implantation, parental involvement and education level, duration and cause of hearing loss, how the implant is situated in the cochlea, the overall health of the cochlear nerve, and individual capabilities of relearning are considered to contribute to this variation.

History

André Djourno and Charles Eyriès invented the original cochlear implant in 1957. Their design distributed stimulation using a single channel.

William House also invented a cochlear implant in 1961. In 1964, Blair Simmons and Robert L. White implanted a single-channel electrode in a patient's cochlea at Stanford University. However, research indicated that these single-channel cochlear implants were of limited usefulness because they cannot stimulate different areas of the cochlea at different times to allow differentiation between low and mid-to-high frequencies as required for detecting speech.

The next step in the development of the CI was its clinical trial on a cohort of patients. In the late 1960s, Robin Michelson and colleague Melvin Bartz constructed a cochlear device with biocompatible materials that can be implanted in human patients. This system was implanted in 4 patients, and the report of the hearing results was a watershed for clinically applicable cochlear implants. Robin Michelson, Robert Schindler, and Michael Merzenich at the University of California, San Francisco (UCSF), conducted these experiments in 1970 and 1971. Michelson, a clinical pioneer, and Merzenich, a talented basic scientist with a solid foundation in neurophysiology, were integral in the development of the UCSF cochlear implant team. Michelson was recognized for implanting a single-channel device into a congenitally deaf woman. She demonstrated auditory sensations from stimulation, as well as pitch perception for stimulus frequencies less than 600 Hz. Unfortunately, this patient had no word recognition. His pioneering work was presented, but not well-received at the 1971 annual meeting of the American Otological Society (Michelson, 1971 and Merzenich et al., 1973). In 1973, the first international conference on the "electrical stimulation of the acoustic nerve as a treatment for profound sensorineural deafness in man" was organized in San Francisco.

NASA engineer Adam Kissiah started working in the mid-1970s on the design for a cochlear implant. Kissiah used his knowledge learned while working as an electronics instrumentation engineer for NASA. This work took place over three years, when Kissiah would spend his lunch breaks and evenings in Kennedy Space Center's technical library, studying the impact of engineering principles on the inner ear. In 1977, NASA helped Kissiah obtain a patent for his cochlear implant; Kissiah later sold the patent rights. A commercial product based on Kissiah's design, developed by BIOSTIM Inc., was tested but failed to reach the marketplace.

The modern multi-channel cochlear implant was independently developed and commercialized by two separate teams—one led by Graeme Clark in Australia and another by Ingeborg Hochmair and her future husband, Erwin Hochmair in Austria, with the Hochmairs' device first implanted in a person in December 1977 and Clark's in August 1978. The Hochmairs' 1977 implant, though an early milestone, did not in its original 8-channel form lead directly to the modern device. Testing of that first system failed to produce open speech understanding and the Hochmairs changed their approach. It was Clark's multi-channel design, commercialized as the Nucleus device by Cochlear Limited, that became the first multi-channel cochlear implant to receive FDA approval in 1985, and successive iterations of the Nucleus device went on to become the most widely used cochlear implants in the world.

Sign in to keep reading

6 more chapters are free with a Lably account.

More in Agriculture